Skip to main content
. Author manuscript; available in PMC: 2021 Apr 19.
Published in final edited form as: Cell Rep. 2021 Apr 6;35(1):108962. doi: 10.1016/j.celrep.2021.108962

Figure 3. Antibody protection against lethal MAYV challenge.

Figure 3.

Four-week-old C57BL/6J female mice were treated with 100 μg of anti-Ifnar1 mAb 1 day before subcutaneous inoculation of MAYV-BeH407.

(A and B) A single 100-μg dose of anti-MAYV mAbs was administered by intraperitoneal injection 1 day before virus inoculation. The mAbs exhibited a range of activity with some showing >50% protection (A) and others <50% (B). Data are from two experiments.

(C and D) Combination therapy of an anti-MAYV E2 B domain mAb (MAY-134) and anti-MAYV E2 A domain mAbs. C57BL6/J mice were treated with 100 μg of anti-Ifnar1 mAb 1 day before subcutaneous virus inoculation. (C) Two days after infection, mice were treated with 200 μg of MAY-10 or MAY-134 or 100 μg each of MAY-10 and MAY-134. (D) Two days after infection, mice were treated with 200 μg of MAY-108 or MAY-134 or 100 μg each of MAY-108 and MAY-134 (two experiments, n = 8; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; log-rank test with Bonferroni correction compared to isotype control mAb). See also Figure S3.